Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics

Bibliographic Details
Main Authors:	Harvey, Christopher, Elpek, Kutlu, Duong, Ellen, Simpson, Tyler, Shu, ChengYi J, Shallberg, Lindsey, Wallace, Matthew, Sathyanarayanan, Sriram, Mabry, Robert, Briskin, Michael, Michaelson, Jennifer, Gajewski, Thomas F
Format:	Online
Language:	English
Published:	BioMed Central 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645516/

id	pubmed-4645516
recordtype	oai_dc
spelling	pubmed-46455162015-11-20 Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics Harvey, Christopher Elpek, Kutlu Duong, Ellen Simpson, Tyler Shu, ChengYi J Shallberg, Lindsey Wallace, Matthew Sathyanarayanan, Sriram Mabry, Robert Briskin, Michael Michaelson, Jennifer Gajewski, Thomas F Oral Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4645516/ http://dx.doi.org/10.1186/2051-1426-3-S2-O9 Text en Copyright © 2015 Harvey et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Harvey, Christopher Elpek, Kutlu Duong, Ellen Simpson, Tyler Shu, ChengYi J Shallberg, Lindsey Wallace, Matthew Sathyanarayanan, Sriram Mabry, Robert Briskin, Michael Michaelson, Jennifer Gajewski, Thomas F
spellingShingle	Harvey, Christopher Elpek, Kutlu Duong, Ellen Simpson, Tyler Shu, ChengYi J Shallberg, Lindsey Wallace, Matthew Sathyanarayanan, Sriram Mabry, Robert Briskin, Michael Michaelson, Jennifer Gajewski, Thomas F Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics
author_facet	Harvey, Christopher Elpek, Kutlu Duong, Ellen Simpson, Tyler Shu, ChengYi J Shallberg, Lindsey Wallace, Matthew Sathyanarayanan, Sriram Mabry, Robert Briskin, Michael Michaelson, Jennifer Gajewski, Thomas F
author_sort	Harvey, Christopher
title	Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics
title_short	Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics
title_full	Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics
title_fullStr	Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics
title_full_unstemmed	Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics
title_sort	efficacy of anti-icos agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics
description
publisher	BioMed Central
publishDate	2015
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645516/
_version_	1613501463750770688

Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics

Similar Items